For all categories except the ‘100% squamous’ category, treatment groups had to consist of ≥80% of patients with no tumor EGFR/ALK aberrations to be included in the mOS summary to align as closely as possible with current FDA/EMA-approved indications for anti-PD-(L)1 therapy. The gene discussed is EGFR; the disease is neoplasm.